Luis Cardenas
Family · Florida City, FLNPI 1609492685
Payments from drug & device makers
Across 97 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$321
- AbbVie$257
- Kowa Pharmaceuticals America, Inc.$183
- Novo Nordisk$153
- Novartis$109
- GSK$102
- plus $754 from 13 others
What the payments were for
- Food & beverage$1,879100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $321 |
| AbbVie | 16 | $257 |
| Kowa Pharmaceuticals America, Inc. | 8 | $183 |
| Novo Nordisk | 7 | $153 |
| Novartis | 6 | $109 |
| GSK | 6 | $102 |
| Lilly USA, LLC | 6 | $101 |
| Scilex Pharmaceuticals Inc. | 5 | $100 |
| Boehringer Ingelheim | 5 | $93 |
| Biohaven Pharmaceuticals, Inc. | 4 | $92 |
| Pfizer | 5 | $92 |
| Merck | 3 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
How this compares
$1,879 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 140 | $65,153 |
| EliquisApixaban | 69 | $48,995 |
| FarxigaDapagliflozin Propanediol | 60 | $38,175 |
| EntrestoSacubitril/Valsartan | 30 | $16,810 |
| TradjentaLinagliptin | 12 | $9,141 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,728 |
| LumiganBimatoprost | 16 | $4,646 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $3,740 |
| Memantine Hcl ErMemantine Hcl | 22 | $3,673 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,052 |
| Gabapentin | 155 | $2,791 |
| Mirtazapine | 89 | $2,037 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $1,962 |
| Levothyroxine Sodium | 154 | $1,875 |
| Pregabalin | 16 | $1,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Tradjenta | $93 | $74,294152 claims |
| PfizerEliquis | $92 | $48,99569 claims |
| AstraZenecaFarxiga | $321 | $38,17560 claims |
| NovartisEntresto | $109 | $16,81030 claims |
| AbbVieLumigan, Combigan, Synthroid | $257 | $7,93043 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,875154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Florida City
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.